STShiu Ying Tsao

Shiu Ying Tsao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shiu Ying Tsao has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • S. F. Leung

    Department of Clinical Oncology, Chinese University of Hong Kong

    4 shared publications
  • W. Shiu

    Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, China

    4 shared publications
  • P. Teo

    Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, China

    3 shared publications
  • Peter Yu

    Clinical Oncology Department, Prince of Wales Hospital, Hong Kong

    3 shared publications
  • S.F. Leung

    Department of Clinical Oncology at the Sir Y.K. Pao Cancer Centre, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong

    3 shared publications
  • W. Foo

    Radiotherapy and Oncology Division, Queen Elizabeth Hospital, Kowloon China

    3 shared publications

Latest Publications

  • Open Access

    Perspectives of traditional Chinese medicine to patch up immune checkpoint blockers

    by Shiu Ying Tsao

    In this era of cancer immunotherapy, the response rates of immune checkpoint blockers (ICBs) are still too low and the adverse events may also be significant. Of the ways of patching up such deficits, chemotherapy (ChT), especially if metronomic, seems promising, especially as immunity induced by immunogenic cell death (ICD) may be preserved. However, side effects, e.g., lymphocytopenia and interstitial pneumonitis cannot be ignored; eventually, resistance may also ensue. Vascular endothelial growth factors (VEGFs), being potent angiogenic factors, promote cancer cells’ purposeful angiogenesis rendering an extremely resistant tumor microenvironment (TME). This highly evasive and extremely resilient TME actually demands multi-agent, multi-target agents as currently in use through traditional Chinese medicine (TCM). With a good track record of 3,000 years, TCM is favored by mainland Chinese cancer patients. Although TCM had been criticized as unscientific and imprecise, recently, artificial intelligence (AI) technologies serve to elucidate the sound scientific basis and validity of TCM. Several TCM preparations having anti-VEGF actions are found; others suppress immune checkpoints. Especially, these herbs’ multi-prong approach appears to be more effective than Western medicine’s primarily monotherapy approach if one wishes to eradicate the very resistant TME. A “bonus” point is that some autoimmune-related adverse side effects of ICBs may also be reduced by TCM. Nevertheless, as the TCM experience is mostly anecdotal, robust clinical trials are mandatory. Moreover, other TCM problems, e.g., herbal batch variations and consistency and uniformity of herbal prescriptions are outstanding. Invariably, TCM prescriptions have daily variations as the practice of “syndrome differentiation” is hailed. Despite experienced TCM practitioners would refuse to give up their time-honored traditional practice, the multi-prong approach is still very attractive for the undue resilience of TME, let alone its good safety profile, ready availability, and eminent affordability. Although the passage is dark, light is now appearing at the end of the tunnel.


  • Open Access

    Perspectives of vitamin C upregulating regulatory T cells in the era of thrombopoietin receptor agonists for immune thrombocytopenia

    by Shiu Ying Tsao

    Background: Immune thrombocytopenia (ITP) is a rare disorder involving excessive peripheral destruction of platelets and inadequate bone marrow platelet production due to autoimmune reactions against megakaryocytes. Diagnosis is usually by the exclusion of primary causes; its rarity would only permit trial and error therapy experience.Historically, for ITP, oral ascorbic acid (AA) gave inconsistent results. However, unlike other nutrients, AA is found to have an exceptionally tight intestinal absorption restriction mandating intravenous delivery for any therapeutic purposes. Recently, as there is more pre‐clinical evidence of AA restoring regulatory T cells (Tregs) by robust demethylation, the historical oral route was likely to be the “bottle neck” restricting effective blood levels. During this era of thrombopoietin receptor agonists (TPO‐RAs), planned tapering is often required upon discontinuation but unplanned discontinuations, for example, due to side effects, are more problematic. Moreover, combinations with TPO‐RAs are currently being tried using steroids and rituximab except rituximab is inappropriate during pandemics. Notably, with the indirect (but prognostically relevant) action of TPO‐RAs on Tregs, boosting Treg functions by adding other Treg active agents, for example, steroids or AA, seems appropriate, especially if without added toxicity upon combining.Conclusions: With updated pharmacokinetic concepts, it is timely to repeat AA clinical trials for ITP but using intravenous administration. Initially, this may be on compassionate grounds for its probable role as an adjunct to TPO‐RAs for unsuccessful tapering and, especially, for all unplanned discontinuations of TPO‐RAs. Such off‐label usage of AA is justified because of AA's robust pre‐clinical evidence on demethylation and initial clinical experience (despite the inappropriate administrative route). Moreover, moderate intravenous AA dosages have one of the best safety profiles, let alone its eminent affordability. Admittedly, after the initial clinical experience, more systematic trials on AA are required, especially for the most appropriate dosage range and its efficacy as monotherapy.

  • Open Access

    Potential of mRNA vaccines to become versatile cancer vaccines

    by Shiu-Ying Tsao

    Potential of mRNA vaccines to become versatile cancer vaccines


  • Open Access

    Embracing cancer immunotherapy with vital micronutrients

    by Raymond C-F Yuen, Shiu-Ying Tsao

    Embracing cancer immunotherapy with vital micronutrients


  • Open Access

    The Role of Metronomic Chemotherapy in the Era of Cancer Immunotherapy: An Oncologist’s Perspective

    by S.Y. Tsao

    Metronomic chemotherapy (MCTX) encompasses a set of chemotherapy (CTX) doses significantly below the conventional maximum tolerated dose (MTD) and delivered largely continually (without the prolonged drug-free breaks typical of MTD CTX).


  • A Pilot Study on the Feasibility of Real-Time Calculation of Three-Dimensional Dose Distribution for 153 Sm-EDTMP Radionuclide Therapy Based on the Voxel S -Values

    by Gan Feng, Chen Lixin, Liu Xiaowei, Shiu Ying Tsao, Zhang Weiguang, Fan Wei

    Objective: Using 153 Sm-EDTMP therapy for bone metastases from nasopharyngeal cancer (NPC), we attempted a real-time three-dimensional (3D) dose calculation based on the S- value for voxels. The 3D radionuclide uptake data on SPECT images were factored into the precalculations by the Monte Carlo (MC) method. Methods: For the nuclide 153 Sm, the S- value for voxels of size 3.45 × 3.45 × 3.45 mm 3 in a soft tissue phantom was precalculated on a self-developed program built from the MC program EGS4. Based on the SPECT/CT image of the patient, the 3D dose rate distributions were calculated with the S- value method and compared with the direct MC calculation results. The total volume of the whole calculation region and the bone were chosen as the regions of interest (ROIs); additionally, the dose rate volume histograms (DVHs) for the ROIs were also calculated. Results: The iso-dose was administered based on the scan images obtained at 6 hours following injection with the nuclide. In the calculation region, the maximum dose rate was 5.98 × 10 −5 and 6.26 × 10 −5 mGy/(MBq S) for S- value and direct MC calculations, respectively. Once the dose rate was normalized to the maximum dose rate point, the iso-dose curves for both methods of calculation were similar in most regions and reasonably matched the functional image as well. The DVHs of the ROIs indicated that the dose rate distributions were nonuniform, that is, ∼30% of the bone-ROI volume received 10% of the maximum dose rate; however, only 3.8% volume received 50% of the maximum dose rate. Conclusions: Using 153 Sm-EDTMP therapy for bone metastases from NPC, we attempted to supplement the current dosimetry work at the image-level by a pragmatic and real-time dosimetry calculation based on S- value and functional imaging. More accurate dose calculations for patients undergoing radionuclide therapy will depend on the development of higher image resolution in nuclear medicine and warrant further studies to optimize the pharmacokinetics model.


  • Dosimetric analysis of a shielded applicator for nasopharyngeal carcinoma intracavitary brachytherapy: Monte Carlo calculation

    by Li Xin Chen, Xiao Wei Liu, Ri An You, Jian Yang Qian, Zhen Yu Qi, Xiao Wu Deng, Shiu Ying Tsao

    In nasopharyngeal cancer (NPC) intracavitary brachytherapy, an anatomical dose reference point (in line with that for gynecology work), e.g., at the sphenoid floor, is more precise than the empirical point of 1 cm from the source. However, such increases of the single-source-plan treatment distances may deliver excessive doses inferiorly, to the soft palate. As shielding may help, its efficacy was studied by Monte Carlo simulations in water for 20 and 30 mm diameter spherical NP applicators (representing extremes of sizes for the small NP cavity), with/without lead shielding inferiorly, using a single linear Ir-192, 2 mm steps, equal dwell times for 5 (5DP) and 9 dwell positions (9DP). Dose reductions of the selected points of interest ranged from 1.2% to 40.5% for the 20 mm shielded applicator and a range of 2.9% to 17.9%, for the 30 mm shielded applicator. Dose volume histograms of the "region of interest" (ROI)-a cuboid of 4 x 4 x 0.5 cm3 at the most inferior aspect of the applicator, also differed significantly. The highest doses of the 50% (D50) and 20% (D20) volumes of ROI (for 5DP and 9DP plans) were reduced by 11.9% to 17.9% for the 20 mm applicator and a range of 9.0% to 11.5% for the 30 mm shielded applicator. Doses in unshielded directions were insignificantly changed, for example, with a 20 mm applicator simulated in a 5DP plan, the dose distribution close to the source in the unshielded direction has less than 4% difference at the 50% isodose relative to the dose prescription point. For the 30 mm shielded applicator, despite smaller dose reduction percentages, a more pronounced effective dose reduction was obtained than nominal values when considering radiobiological equivalent doses. Our system was demonstrated to be ready for clinical assessment.


  • Distribution of Epstein-Barr virus antigenic sites on the carboxyl terminal end of ribonucleotide reductase against nasopharyngeal carcinoma serum antibodies using an immunoabsorption method

    by R. Hu, D. Chai, T.T.M. Tan, Y.H. Gan, S.H. Chan, S.Y. Tsao, L.H. Gan

    In an attempt to clone and express proteins from the Epstein-Barr virus (EBV) cDNA library to be used as antigens in an enzyme-linked immunosorbent assay (ELISA) format to test against the antibodies found in the sera of nasopharyngeal carcinoma (NPC) patients, we have isolated and characterized three clones. All three clones expressed the same polypeptides of different lengths, which belong to the carboxyl terminal end of the large subunit of ribonucleotide reductase (RR) of the EBV genome. All three clones were found to be immunogenic and could be used in an IgA and IgG ELISA against the NPC sera with various degrees of sensitivity and specificity. Because the clones varied in length, this difference provides a simple system to determine where most of the antibody epitopes lies on the protein. We designed an immunoabsorption assay and a mathematical model to help map the segment of the polypeptide most immunogenic to 43 NPC patients. Results were unexpected: 77% of the patients were most immunogenic to region z, which was the smallest fragment among the three fragments studied. Fragment z was only 33 amino acids in length. Only 14% and 19% of patients showed the most immunogenic region in segment x and y, respectively. This variation could be due to major histocompatibility complex antigens. The patients could be divided into three groups based on the immunoabsorption assays, in which each group responded to a different immunodominant segment in the RR antigen. The largest group responded to an immunodominant segment, which was only 33 amino acids long. This domain was coded for by the gene fragment from nucleotide 78,129 to nucleotide 78,227 of the EBV genome. This segment of the protein would be suitable for further epitope mapping studies. J. Med. Virol. 58:385–396, 1999.

  • Strong association between hyperferritinaemia and metastatic disease in nasopharyngeal carcinoma

    by S. Ho, S.F. Leung, W.T. Leung, S.Y. Tsao, W.H. Kwan, P. Choi, P.J. Johnson


  • No association between HLA DQ and -DR genotypes with nasopharyngeal carcinoma in southern Chinese

    by Philip Kam Tao Li, Angela S.Y. Poon, Shiu Ying Tsao, Stephen Ho, John S.L. Tam, Alex K.L. So, Kar Neng Lai